Novel strategy for the development of radioresistance breast cancer cell line
Purpose: Fractionated radiation dose therapy is a routine procedure for the breast cancer treatment. However, despite of continuous improvement, tumor recurrence occurs in high proportion of the patients. There is a need of suitable radioresistance cell line system to study the properties of tumor recurrence. But, developing a radioresistant cancer cell line is a time requiring process. It requires a multiple radiation dosages for a period of three to four months. The present study aims for the new strategy to develop a radioresistant breast cancer MCF-7 cell line.
Methods: The cells were exposed to 4Gy dosage of ϒ rays prior to 10Gy dose and subjected for clonogenic assay. The cells survived in the clonogenic assay were pooled and named as RR-MCF-7. These cells were subjected to Bcl-2 analysis, apoptotic assay and LDH assay.
Results: Developed cell line, RR-MCF-7 showed enhanced expression of Bcl-2 protein, which resulted in the declined apoptotic cell percentage. Though there was destabilization in the membrane of the irradiated cells, there was no significant difference observed in LDH level. Cloning efficiency of the 10 Gy exposed cells was found to be more when it was given a 4 Gy of prior dosage. The cells survived with this dosage showed the resistant character.
Conclusion: The approach followed in the current study for developing radioresistant cell line has reduced the time and dose requirement, also succeeded in obtaining resistant characters in it.
Shimura T, Kakuda S, Ochiai Y, et al. Acquired radioresistance of human tumor cells by DNA-PK/AKT/GSK3beta mediated cyclin D1 overexpression. Oncogene. 2010;29:4826–37.
Zafarana G, Brintow RG. Tumor senescence and radio-resistant tumor-initiating cells (TICs): let sleeping dogs lie. Breast Cancer Res. 2010; 12:111.
Diehn M, Cho RW, Lobo NA, et al. Association of reactive oxygen species levels and radio- resistance in cancer stem cells. Nature. 2009; 458:780-3.
Woodward WA, Bristow RG. Radio-sensitivity of cancer initiating cells and normal stem cells. Seminars Radiat Oncol. 2009;19:87-95.
Bao S, Mn Q, McLendon RE, et al. Glioma stem cells promote radio-resistance by preferential activation of DNA damage response. Nature. 2006;444:756-60.
Ji-Yu Li, Yu-Yang Li, We Jin, et al. ABT-737 reverses the acquired radioresistance of breast cancer cells by targeting Bcl-2 and Bcl-XL. J Exp Clin Cancer Res. 2012;31:102.
Li Xie, Xianrang Song, Jinming Yu, et al. Fractionated irradiation induced radio-resistant esophageal cancer EC109 cells seem to be more sensitive to chemotherapeutic drugs. J Exp Clin Cancer Rese. 2009;28:68.
Ribble D, Goldstein NB, Norris DA, Shelloman YG. A simple technique for quantifying apoptosis in 96 well plates. BMC Biotechnology. 2005;5:12.
Haggins CF. Membrane permeability transporters and channels: from disease to structure and back. Curr Opin Cell Biol. 1999;11:495-9.
Ogawa K, Utsunomiya T, Mimori K, et al. Differntial gene expression profiles of radioresistance pancreatic cancer lines established by fractionated irradiation. Int J Oncol. 2006;28:705-13.
Rycai K Tanq DG. Cancer stem cells and radioresistance. Int J Radiat Biol. 2014; 90(8):615-21.
Im CN, Kim BN, Moon EY, et al. Characterization of H460R, a radioresistant human cancer cell line, and involvement of syntrophin beta 2(SNTB2) in radioresistance. Genomics Inform. 2013;11(4):245-53.
Hill BT, Moran E, Etievant C, et al: Low-dose twice-daily fractionated X-irradiation of ovarian tumor cells in vitro generates drug-resistant cells overexpressing two multidrug resistance-associated proteins, P-glycoprotein and MRP1. Anticancer Drugs. 2000;11(3):193-200.
Nielsen D, Maare C, Eriksen J, et al. Expression of P-glycoprotein and multidrug resistance associated protein in Ehrlich ascites tumor cells after fractionated irradiation. Int J Radiat Oncol Biol Phys. 2001;51(4):1050-1057.
Bottke D, Koychev D, Busse A, et al. Fractionated irradiation can induce functionally relevant multidrug resistance gene and protein expression in human tumor cell lines. Radiat Res. 2008;170(1):41-48.
Condon LT, Ashman JN, Ell SR, et al. Overexpression of Bcl-2 in squamous cell carcinoma of the larynx: a marker of radioresistance. Int J Cancer. 2002;100(4): 472-5.
This work is licensed under a Creative Commons Attribution 3.0 License.
International Journal of Cancer Therapy and Oncology (ISSN 2330-4049)
© International Journal of Cancer Therapy and Oncology (IJCTO)
To make sure that you can receive messages from us, please add the 'ijcto.org' domain to your e-mail 'safe list'. If you do not receive e-mail in your 'inbox', check your 'bulk mail' or 'junk mail' folders.